<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2219">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04470297</url>
  </required_header>
  <id_info>
    <org_study_id>MELCOV2020</org_study_id>
    <nct_id>NCT04470297</nct_id>
  </id_info>
  <brief_title>Melatonin Agonist on Hospitalized Patients With Confirmed or Suspected COVID-19</brief_title>
  <official_title>Adjuvant Therapeutic Effects of Melatonin Agonist on Hospitalized Patients With Confirmed or Suspected COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Associação Fundo de Incentivo à Pesquisa</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Associação Fundo de Incentivo à Pesquisa</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      COVID-19 is impacting on health systems in Brazil and worldwide. Reducing the risk of&#xD;
      clinical deterioration and prolonged disease duration in hospitalized patients with COVID-19&#xD;
      may alleviate the burden caused by the pandemic. Melatonin (N-acetyl-5-methoxytryptamine) has&#xD;
      demonstrated antiapoptotic, antioxidative, and anti-inflammatory roles and has been suggested&#xD;
      as a potential protector against organ injuries and even mediate lower mortality rates after&#xD;
      polymicrobial sepsis in animal models. Melatonin agonists may modulate protective effects&#xD;
      against acute lung injury and play a clinical role in individuals with SARS-CoV-2 infection.&#xD;
      The investigators proposed a clinical trial testing the effects of ramelteon 8mg in&#xD;
      hospitalized patients with COVID-19.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) pandemic, also denominated&#xD;
      Coronavirus Disease 2019 (COVID-19), is currently challenging health systems in Brazil and&#xD;
      worldwide. The mortality rate of confirmed cases of COVID-19 in Brazil seems to be close to&#xD;
      twice that of countries like Germany and Canada. (1-3) The resulted viral interstitial&#xD;
      pneumonia can lead to severe hypoxemic respiratory failure, overcrowded intensive care units&#xD;
      (ICUs), shortages of equipment and personnel, and increased mortality. (4-6)&#xD;
&#xD;
      Some reasons for higher mortality risk in Brazil can be related to an increased propensity of&#xD;
      clinical worsening in hospitalized patients. Consequently, reducing the risk of clinical&#xD;
      deterioration and prolonged disease duration in hospitalized patients with mild-to-moderate&#xD;
      COVID-19 has become a priority to reduce the burden of such pandemic and the admission to&#xD;
      ICUs. However, to our knowledge, few and complex specific interventions have been tested&#xD;
      targeting outcomes related to a reduction of the immediate risk of severe disease and&#xD;
      prolonged hospitalization in inpatients with mild-to-moderate clinical signs and symptoms.&#xD;
&#xD;
      Melatonin (N-acetyl-5-methoxytryptamine) is a hormone synthesized mainly by the pineal gland&#xD;
      and also by other nonendocrine organs, including the immune system. Among its multiple&#xD;
      properties, melatonin has demonstrated antiapoptotic, antioxidative, and anti-inflammatory&#xD;
      roles exerted via both receptor-dependent and receptor-independent signalling cascades. (7,8)&#xD;
      It has been suggested that melatonin receptors activation protects against organ injuries.&#xD;
      (9-10). Additionally, melatonin receptors can mediate lower mortality rates after&#xD;
      polymicrobial sepsis in animal models. (11)&#xD;
&#xD;
      Melatonin potentially modulates immune response by enhancing the secretion of&#xD;
      anti-inflammatory cytokines including IL-10, which is involved in the Th2-like immune&#xD;
      response. (12) IL-10 has effects on a myriad of cell types and, in lung cells under damaging&#xD;
      circumstances, its production turns undermined. (13) Recent findings indicated that melatonin&#xD;
      receptors are modulators of protective effects against acute lung injury induced by the&#xD;
      ventilator in rats through the up-regulation of IL-10 production. (14) This evidence upsurged&#xD;
      testing the effects of ramelteon, a potent and highly selective agonist of high-affinity&#xD;
      melatonin receptors 1 (MT1) and MT2, which further displays antioxidative and&#xD;
      anti-inflammatory properties. (15-17) Melatonin agonism may play a clinical role in&#xD;
      individuals with acute lung injuries, including those induced by SARS-CoV-2 infection, which&#xD;
      has not yet been investigated. The investigators designed a clinical trial testing standard&#xD;
      care versus ramelteon 8mg under diverse clinical and laboratory outcomes related to the&#xD;
      COVID-19 in hospitalized patients with this condition.&#xD;
&#xD;
      References&#xD;
&#xD;
        1. Robert Koch Institut. Coronavirus Disease 2019 (COVID-19) Daily Situation Report of the&#xD;
           Robert Koch Institute. Available from:&#xD;
           https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Situationsberichte/Gesamt.h&#xD;
           tml Updated 14.05.20&#xD;
&#xD;
        2. DATASUS. Ministério da Saúde do Brasil. Available from: https://covid.saude.gov.br/.&#xD;
           Atualizada em: 14/05/2020&#xD;
&#xD;
        3. Government of Canada. Coronavirus Disease 2019 (COVID-19): Daily Epidemiology Update.&#xD;
           Available from:&#xD;
           https://www.canada.ca/en/public-health/services/diseases/2019-novel-coronavirus-infectio&#xD;
           n.html?topic=tilelink#a1. Updated 14.05.20.&#xD;
&#xD;
        4. P.H.S. Pelicioni, S.R. Lord. COVID-19 will severely impact older people's lives, and in&#xD;
           many more ways than you think!. Braz J Phys Ther, (2020),&#xD;
           http://dx.doi.org/10.1016/j.bjpt.2020.04.005&#xD;
&#xD;
        5. [3] R.D. Branson, D.R. Hess, L. Rubinson. SARS CoV-2: Guidance Document. American&#xD;
           Association for Respiratory Care, (2020),&#xD;
&#xD;
        6. World Health Organization. Coronavirus Disease 2019 (COVID-19) Situation Report 46.&#xD;
           (2020)&#xD;
&#xD;
        7. Jockers R, Delagrange P, Dubocovich ML, Markus RP, Renault N, Tosini G, Cecon E, Zlotos&#xD;
           DP. Update on melatonin receptors: IUPHAR Review 20. Br J Pharmacol. 2016;173:2702-2725.&#xD;
           doi: 10.1111/bph.13536.&#xD;
&#xD;
        8. Radogna F, Paternoster L, Albertini MC, Cerella C, Accorsi A, Bucchini A, Spadoni G,&#xD;
           Diamantini G, Tarzia G, De Nicola M, et al. Melatonin antagonizes apoptosis via receptor&#xD;
           interaction in U937 monocytic cells. J Pineal Res. 2007;43:154-162. doi:&#xD;
           10.1111/j.1600-079X.2007.00455.x.&#xD;
&#xD;
        9. Lochner A, Genade S, Davids A, Ytrehus K, Moolman JA. Short- and long-term effects of&#xD;
           melatonin on myocardial post-ischemic recovery. J Pineal Res. 2006;40:56-63. doi:&#xD;
           10.1111/j.1600-079X.2005.00280.x.&#xD;
&#xD;
       10. Rezzani R, Rodella LF, Bonomini F, Tengattini S, Bianchi R, Reiter RJ. Beneficial&#xD;
           effects of melatonin in protecting against cyclosporine A-induced cardiotoxicity are&#xD;
           receptor-mediated. J Pineal Res. 2006;41:288-295. doi: 10.1111/j.1600-079X.2006.00368.x.&#xD;
&#xD;
       11. Fink T, Glas M, Wolf A, Kleber A, Reus E, Wolff M, Kiefer D, Wolf B, Rensing H, Volk T,&#xD;
           Mathes AM. Melatonin receptors mediate improvements of survival in a model of&#xD;
           polymicrobial sepsis. Crit Care Med. 2014;42:e22-e31. doi: 10.1097/CCM.0b013e3182a63e2b.&#xD;
&#xD;
       12. Ren Wenkai, Liu Gang, Chen Shuai, Yin Jie, Wang Jing, Tan Bie, Wu Guoyao, Bazer Fuller&#xD;
           W., Peng Yuanyi, Li Tiejun, Reiter Russel J., Yin Yulong. Melatonin signalling in T&#xD;
           cells: Functions and applications. Journal of Pineal Research. 2017;62(3):e12394. doi:&#xD;
           10.1111/jpi.12394.&#xD;
&#xD;
       13. Hokenson MA, Wang Y, Hawwa RL, Huang Z, Sharma S, Sanchez-Esteban J. Reduced IL-10&#xD;
           production in fetal type II epithelial cells exposed to mechanical stretch is mediated&#xD;
           via activation of IL-6-SOCS3 signalling pathway. PLoS One. 2013;8:e59598. doi:&#xD;
           10.1371/journal.pone.0059598.&#xD;
&#xD;
       14. Wu GC, Peng CK, Liao WI, Pao HP, Huang KL, Chu SJ. Melatonin receptor agonist protects&#xD;
           against acute lung injury induced by ventilator through up-regulation of IL-10&#xD;
           production. Respir Res. 2020 Mar 6;21(1):65. doi: 10.1186/s12931-020-1325-2.&#xD;
&#xD;
       15. Mathes AM, Kubulus D, Waibel L, Weiler J, Heymann P, Wolf B, Rensing H. Selective&#xD;
           activation of melatonin receptors with ramelteon improves liver function and hepatic&#xD;
           perfusion after hemorrhagic shock in the rat. Crit Care Med. 2008;36:2863-2870. doi:&#xD;
           10.1097/CCM.0b013e318187b863.&#xD;
&#xD;
       16. Shimizu N, Nozawa M, Sugimoto K, Yamamoto Y, Minami T, Hayashi T, Yoshimura K, Ishii T,&#xD;
           Uemura H. Therapeutic efficacy and anti-inflammatory effect of ramelteon in patients&#xD;
           with insomnia associated with lower urinary tract symptoms. Res Rep Urol.&#xD;
           2013;5:113-119.&#xD;
&#xD;
       17. Zhou W, Zhang X, Zhu CL, He ZY, Liang JP, Song ZC. Melatonin receptor agonists as the&#xD;
           &quot;Perioceutics&quot; agents for the periodontal disease through modulation of Porphyromonas&#xD;
           gingivalis virulence and inflammatory response. PLoS One. 2016;11:e0166442. doi:&#xD;
           10.1371/journal.pone.0166442&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2020</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to resolution of symptoms [National Early Warning Score 2 (NEWS2) of 0]</measure>
    <time_frame>enrollment is day 0</time_frame>
    <description>Defined as a National Early Warning Score 2 (NEWS2) of 0 maintained for 24 hours [Time Frame: Assessed daily (enrollment is day 0)] The NEWS consists of a simple aggregate scoring system based on physiological measurements, regularly registered in inpatient settings, including six parameters: respiration rate, oxygen saturation, systolic blood pressure, pulse rate, level of consciousness or new confusion, and temperature.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical worsening to critical COVID-19 illness</measure>
    <time_frame>until Day 30</time_frame>
    <description>Critical COVID-19 illness as a composite of admission to the intensive care unit (ICU), invasive ventilation, or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of supplemental oxygen therapy</measure>
    <time_frame>until day 14</time_frame>
    <description>Measured by duration of use of supplemental oxygen (if applicable)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of mechanical ventilation (if applicable)</measure>
    <time_frame>until day 30</time_frame>
    <description>Measured by duration of use of mechanical ventilation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of hospitalisation</measure>
    <time_frame>until day 30</time_frame>
    <description>Measured by duration of hospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with virologic clearance in nasopharyngeal swab RT-PCR</measure>
    <time_frame>Day 14</time_frame>
    <description>Presence or absence of SARS-CoV-2 Viral RNA in nasopharyngeal swab or lower respiratory secretions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-reactive protein (CRP) level's reduction</measure>
    <time_frame>Days 3, 5 and 8</time_frame>
    <description>Reduction of C-reactive protein levels &gt; 50% in comparison with PCR levels at the admission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of New Onset Lymphopenia</measure>
    <time_frame>Through study completion, average of 15 days</time_frame>
    <description>Incidence of new onset lymphopenia during hospitalization measured by blood draw</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Direct bilirubin level's reduction</measure>
    <time_frame>Measured in study Days 3, 5, and 8</time_frame>
    <description>Reduction of mean direct bilirubin levels in comparison with levels at the admission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side Effects</measure>
    <time_frame>until day 14</time_frame>
    <description>Differences in number of patients in study arms who experienced side effects</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Covid19</condition>
  <condition>Lung Injury</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A placebo with the same physical characteristics of the experimental drug pill will be administered at the same time and daily schedule as the experimental intervention for 10 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ramelteon</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A pill containing ramelteon 8mg will be administered daily at bedtime for 10 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ramelteon 8mg</intervention_name>
    <description>Standard care combined with oral placebo or ramelteon 8mg at bedtime for 10 days</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Ramelteon</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Individuals (or legally authorized representative) providing written informed consent&#xD;
             prior to initiation of any study procedures.&#xD;
&#xD;
          2. Male or non-pregnant female adult ≥18 years of age at time of enrollment&#xD;
&#xD;
          3. Subject consents to randomization within 48 hours of hospital admission&#xD;
&#xD;
          4. Symptom duration of 14 days or less upon recruitment&#xD;
&#xD;
          5. At least one of the following:&#xD;
&#xD;
               1. Radiographic infiltrates by imaging (chest x-ray or CT scan), OR&#xD;
&#xD;
               2. Clinical assessment (evidence of rales/crackles on the exam) AND SpO2 ≤ 94% on&#xD;
                  room air&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Mild COVID-19 disease (minor clinical symptoms, imaging does not show signs of lung&#xD;
             inflammation)&#xD;
&#xD;
          2. Recent history of or any in-hospital exposure to investigational medications targeting&#xD;
             COVID-19&#xD;
&#xD;
          3. ALT/AST &gt; 5 times the upper limit of normal.&#xD;
&#xD;
          4. Known hypersensitivity to ramelteon&#xD;
&#xD;
          5. Pregnancy&#xD;
&#xD;
          6. Severe hepatic insufficiency&#xD;
&#xD;
          7. Fluvoxamine use&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dalva Poyares, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Associação Fundo de Incentivo a Pesquisa</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ronaldo D Piovezan, PhD</last_name>
    <phone>+5511984153364</phone>
    <email>rdpiovezan@gmail.com</email>
  </overall_contact>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 12, 2020</study_first_submitted>
  <study_first_submitted_qc>July 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 14, 2020</study_first_posted>
  <last_update_submitted>July 22, 2020</last_update_submitted>
  <last_update_submitted_qc>July 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Associação Fundo de Incentivo à Pesquisa</investigator_affiliation>
    <investigator_full_name>Ronaldo Delmonte Piovezan</investigator_full_name>
    <investigator_title>PhD</investigator_title>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>Acute Distress Respiratory Syndrome</keyword>
  <keyword>Melatonin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Injury</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

